Imraldi 40 mg solution for injection in pre-filled pen

DRUG2 trials

Sponsors

Diakonhjemmet Sykehus AS, University Of Medicine And Pharmacy Carol Davila Bucharest, Medical University Of Vienna, Karolinska University Hospital, Centre Hospitalier Universitaire De Bordeaux

Conditions

Rheumatoid arthritisRheumatoid arthritis (RA)

Phase 3

Combination of baricitinib and anti-TNF vs. baricitinib alone in patients with rheumatoid arthritis: a randomized placebo-controlled phase-III trial - CRI-RA

RecruitingCTIS2024-511442-39-00

Centre Hospitalier Universitaire De BordeauxRheumatoid arthritis (RA)

Start: 2025-02-05Target: 169Updated: 2025-12-10

Phase 4

A multi-center, open, randomized, 18-month, parallel-group, superiority study to compare the effect of proactive therapeutic drug monitoring versus standard of care with regards to maintenance of sustained disease control without flare in adults with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor

RecruitingCTIS2023-510184-35-00

Diakonhjemmet Sykehus AS, University Of Medicine And Pharmacy Carol Davila Bucharest, Medical University Of Vienna, Karolinska University HospitalRheumatoid arthritis

Start: 2024-08-20Target: 410Updated: 2025-09-12